Medscape

GAUSS-3: Evolocumab Cuts LDL-C in Statin-Intolerant Patients

CHICAGO, IL (updated) — Six-month treatment with the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab (Repatha, Amgen) can dramatically reduce LDL-cholesterol levels in ...
Newsday

New Drug Lowers Cholesterol Beyond What Statins Can Do, Study Finds

Two studies find that an experimental cholesterol-lowering drug is effective when combined with statins and beats another add-on drug when it comes to helping hard-to-treat patients. The drug, ...
Healio

Pre-PCI evolocumab did not prevent microvascular dysfunction when added to statin therapy

Please provide your email address to receive an email when new articles are posted on . Pretreatment evolocumab did not lower risk for periprocedural microvascular dysfunction in patients undergoing ...
EurekAlert!

PCSK9 inhibitor evolocumab reduces adverse cardiovascular events

PCSK9 Inhibitor Evolocumab Significantly Reduces Adverse Cardiovascular Events When Added to Statin Therapy With No Major Safety Concerns Data from the first successfully completed dedicated outcomes ...
EurekAlert!

PCSK9 inhibitor evolocumab not associated with decline in memory or cognitive function

New trial results show that in patients on statin therapy, the addition of evolocumab did not result in a significant change in cognitive function after 19 months of treatment. A new class of ...
CNN

Experimental daily pill may lower cholesterol in patients who don’t see enough benefit with statins alone, study finds

For some people with high cholesterol, making lifestyle changes and taking routine statin medications may not be sufficient to help them reach their target cholesterol levels. For these patients, a ...
Medscape

Early Evolocumab in Acute Coronary Syndrome Safe, LDL Plummets

PARIS — Adding the PCSK9 inhibitor evolocumab (Repatha, Amgen) to high-intensity statin therapy in the very high-risk setting of acute coronary syndrome (ACS) safely lowers low-density lipoprotein ...
TCTMD

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

The larger risk reductions were not explained by changes in LDL cholesterol, suggesting something else is at play.
Healio

Long-term LDL cholesterol reduction with evolocumab reduces events, including CV death

Data from an open-label extension of the FOURIER study show use of the PCSK9 inhibitor evolocumab for more than 7 years led to durable reductions in LDL and a reduction in CV events, including CV ...
Newsday

New Drug May Help Lower 'Bad' Cholesterol Beyond Statins

A new injectable drug can further knock down cholesterol levels in people who take cholesterol-busting statin medications, according to the results of a global trial. People taking the new therapy ...

People’s Pharmacy: Does cholesterol-lowering drug lead to depression?

Q. I developed severe depression while taking Repatha, the injectable cholesterol lowering drug. It took me a horrible nine months to realize the drug was making me suicidal. If I wasn’t sleeping, I ...